Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Ran Nussbaum is a managing partner and co-founder of The Pontifax Group, which has established three funds with more $200M under management and more than 30 portfolio companies. Over the past eight years, Nussbaum has managed the group's activity alongside Tomer Kariv. He also served as CEO of Biomedix and was NasVax Ltd.'s chairman of the board. Prior to joining Pontifax, he was a partner at Israel's largest business intelligence and strategic consulting firm. Nussbaum's work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Nussbaum serves as a board member of many of the Pontifax Group's portfolio companies, including TheraCoat, CollPlant Ltd., Quiet Therapeutics, Fusimab Ltd. and OCON Medical Ltd., where he is currently chairman of the board.
Venture Capitalist Ran Nussbaum Brings Big Finance to Little Biotechs (4/3/14) Biotech companies don't come into the world fully formed. Like most fledglings, they need guidance to grow, prosper and eventually thrive in public markets. Venture capitalist Ran Nussbaum of the Pontifax Group nurtures tiny biotech and medtech startups, finding capital for their growth and maturation. In this interview with The Life Sciences Report, Nussbaum discusses exciting private equity holdings that are close to going public, and makes a case for one public company he knows quite well.
Three New Picks from the Hot Biotech IPO Market: Ran Nussbaum (8/22/13) Ran Nussbaum, co-founder and managing partner of The Pontifax Group, is a venture capitalist seeking game-changing products that will create real value for patients, pharmas and investors. In this interview with The Life Sciences Report, Nussbaum addresses three public companies in different stages of developmentŚfrom a penny stock with a preclinical value driver to a revenue-generating "larger" small-cap company developing novel products for critical orphan indications. As a bonus, Nussbaum drops two European biotech names that he believes are suffering from anonymity in U.S. markets.
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum Moreá>
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein Moreá>
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak Moreá>